Stocks · News reference
Cantor Fitzgerald analyst Sarah James reiterates MiMedx Group (NASDAQ:MDXG) with a Overweight and maintains $8 price target.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
MIMEDX Group reported second quarter 2026 net sales of $64 million and reiterated its full year financial outlook. The company announced plans to acquire Sanara MedTech in a transformational combination aimed at creating a leading regenerative medicine company and expanding MIMEDX's surgical footprint across multiple surgical subspecialties.
Craig-Hallum analyst Chase Knickerbocker maintains MiMedx Group (NASDAQ:MDXG) with a Buy and raises the price target from $6 to $8.
Filed: 2026-08-11 AccNo: 0001376339-26-000082 Size: 208 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits